Stocks Seeing Further Upside After Initial Advance – U.S. Commentary

Stocks Seeing Further Upside After Initial Advance – U.S. Commentary
After moving notably higher early in the session, stocks have seen further upside over the course of the trading day on Tuesday. The major averages have moved sharply higher after ending the previous session firmly in the red. Currently, the major averages are hovering near their best levels of the day. The Dow is up 357.81 points or 1.4 percent... Read More

Dow rallies by 370 points and is poised for best day in about 2 months as earnings shine

Dow rallies by 370 points and is poised for best day in about 2 months as earnings shine
The Dow Jones Industrial Average was trading sharply higher midday Tuesday, putting blue chips on track to book the best one-day gain since mid August. The Dow DJIA, +1.49% was up about 370 points, or 1.5%, at 25,620. That gain was partly on the back of a surge in shares of component UnitedHealth Group Inc. UNH, +3.42% which was delivering... Read More

Major Averages Climb Firmly Into Positive Territory – U.S. Commentary

Major Averages Climb Firmly Into Positive Territory – U.S. Commentary
Stocks have moved significantly higher in morning trading on Tuesday after ending the previous session mostly lower. The major averages have climbed firmly into positive territory, more than offsetting yesterday’s losses. Currently, the major averages are holding on to strong gains. The Dow is up 223.70 points or 0.9 percent at 25,474.25, the Nasdaq is up 74.48 points or 1... Read More

Noodles & Co. shares jump 12% after upgrade on strength of ‘zoodles’ platform

Noodles & Co. shares jump 12% after upgrade on strength of ‘zoodles’ platform
Noodles & Co. NDLS, +11.50% was upgraded to buy from hold at SunTrust Robinson Humphrey on the strength of “zoodles,” zucchini noodles that offer a low-calorie, healthy alternative. SunTrust raised its price target to $15 from $11. Shares are up nearly 12% in Tuesday trading. SunTrust analysis shows that zoodles have been popular since its launch in May. Analysts led... Read More

Dow’s earnings reporters providing a 92-point boost to futures’ rally

Dow’s earnings reporters providing a 92-point boost to futures’ rally
Of the 30 Dow Jones Industrial Average DJIA, +0.82% components, 29 are trading higher in the premarket, with the three that reported third-quarter earnings accounting for nearly a half of the gains in Dow futures YMZ8, +0.87% Of the other reporters, shares of UnitedHealth Group Inc. UNH, +2.73% climbed 3.2%, Goldman Sachs Group Inc. GS, +2.19% rose 2.2% and Johnson... Read More

Stocks May See Initial Strength On Upbeat Earnings News – U.S. Commentary

Stocks May See Initial Strength On Upbeat Earnings News – U.S. Commentary
After ending yesterday’s trading mostly lower, stocks are likely to show a significant move back to the upside at the start of trading on Tuesday. The major index futures are currently pointing to a higher open for the markets, with the Dow futures up by 217 points. Early buying interest may be generated in reaction to upbeat earnings news from... Read More

Green Organic Dutchman’s stock surges after receipt of medical cannabis sales license

Green Organic Dutchman’s stock surges after receipt of medical cannabis sales license
Shares of Green Organic Dutchman Holdings Ltd. TGODF, -3.99% TGOD, -3.73% surged 5.3% in premarket trade Tuesday, after the organic medical cannabis company said it received its medical sales license from Health Canada. The license is in accordance with the Access to Cannabis for Medical Purposes Regulations for the Canada-based company’s Ancaster, Ontario facility. “As we prepare for our Founders... Read More

Do You Have These Pharma Stocks In Your Portfolio? (EARS, BLRX, OMED…)

Do You Have These Pharma Stocks In Your Portfolio? (EARS, BLRX, OMED…)
Clinical trials are major catalysts for biotech/pharma companies as positive study data can boost the stock price while unfavorable results can send the stocks plummeting. The success rate of phase I clinical programs is the highest, say 63%, while it is the lowest for phase II trials – i.e. 30%. The phase III trials, which are the longest and most... Read More